Membrane-based Cancer Nanovaccines: the Time is Now.

G. Zhao,Y. Jiang,P. Ma,S. Wang,G. Nie,N. Li
DOI: https://doi.org/10.1093/qjmed/hcad089
2023-01-01
QJM
Abstract:The burgeoning field of nanovaccines presents the promise of breakthrough developments in cancer treatment. 1 A nanoscale cancer vaccine platform can generally be formulated by co-encapsulating tumor antigens and immune adjuvant(s) into a suitable carrier to elicit antigen-specific immune responses, leading to safe and potent antitumor immunity. 2 Taking advantage of cell membranes, as crucial mediators of cell–cell interactions and intercellular communication, numerous biomimetic, cell membrane-camouflaged nanovaccines have been developed to enhance the receptor–ligand interactions, and elicit robust antitumor immune responses. 3 Given the growing interest in this approach, here, we present a systematic review of
What problem does this paper attempt to address?